SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Ella Fitzgerald (HR-ML029)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 13judgment calls in the dossier
- 1protocol deviations
- 5orders and referrals without results in the record
- 0evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the hypoglycemia plan (glipizide stopped, glargine reduced and moved to the morning), empagliflozin and semaglutide with peripheral artery disease and retinopathy, low-dose rivaroxaban with aspirin, the decision to defer revascularization during supervised exercise therapy, and the IWGDF risk grading. |
| provenance review | not_started | | | A 1996 wire obituary, the PBS American Masters timeline, a Newsweek obituary, VOA Learning English, and the official foundation page are logged. Every health claim is from these public reports; the type of diabetes and all modern findings are synthetic. |
| safe messaging review | not_started | | | Recent-death rule applies. The 1993 amputations and her death are recorded as history only, in plain sentences; the modern episode does not stage or predict them. No mental-health or substance claim is made. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. She died in 1996, so the rule applies. Every health claim comes from public reports: a 1996 wire obituary, the PBS American Masters timeline, a Newsweek obituary, VOA Learning English, and her foundation’s own page. No medical record, physician statement, family account, biography, or speculation is used. No sick visit is added. No claim concerns mental health or substance use. Her death is recorded in one sentence (CLM-0014), which notes that the cause was not released.
- What is and is not on the public record. The record documents diabetes with eye problems from the 1970s, cataract surgery in the 1970s, intensive care and quintuple-bypass heart surgery in 1986, “circulatory system complications” of diabetes, and the 1993 amputation of both legs below the knee. The type of diabetes, its treatment, every laboratory and imaging value, the grade of retinopathy, the location of the arterial disease, the medicines, and the outcomes in the modern episode are synthetic. No diagnosis beyond these reported conditions is added: kidney function and urine albumin are normal, no neuropathy is diagnosed (protective sensation is intact), and no heart failure, hypertension, or hyperlipidemia diagnosis is coded; the statin, ezetimibe, aspirin, rivaroxaban, and metoprolol are indicated by the coronary and peripheral artery disease. Low glucose readings are part of the synthetic treatment history and are not coded as a separate diagnosis.
- Amputations. The 1993 amputations (CLM-0011) are history only. They fall six years after the true-frame episode, are linked only to the 1993 timeline event, and do not appear in the intake documents. The modern episode neither stages nor predicts them: the arterial disease improves with supervised exercise and medical therapy, no wound occurs, and revascularization is planned if claudication again limits her life or any threat to the limb appears.
- Birth date. April 25, 1917 is from her birth certificate and school records as reported in the 1996 obituary and the PBS timeline; 1918, given in most earlier biographies, is recorded as a conflicting alternative.
- Index age and dates. The index visit on May 11, 2026 maps to May 11, 1987, when she was 70: the year after her 1986 heart surgery, when she was back on stage, and six years before the amputations. The synthetic date of birth is April 25, 1956 (shift 39 years). The visits on May 26, June 15, August 10, and October 26, 2026 map to the same days of 1987. The coronary bypass surgery “last year” in the modern episode stands for the 1986 operation; the medicine start date of June 2, 2025 stands for the treatment begun after it.
- Real people. Her parents, Chick Webb, and her mother’s death appear only in the claims and family history; her mother’s death from a heart attack is the only family history, as the PBS timeline gives it. No modern decision, statement, or health fact is attributed to any real person. Her road manager, dresser, and musicians in the modern episode are unnamed and synthetic. The aliases “Ella Jane Fitzgerald” and “First Lady of Song” appear in no other record, and no other figure with a record is named.
- Equity and access. The modern episode treats access as part of the clinical plan (scheduling around tours, video visits, large print for her vision, drug-cost checks, coordination with clinics in tour cities) and the consultant notes the higher rates of amputation, often without a vascular assessment first, in people with diabetes, in Black Americans, and in people with less access to care, as the ACC/AHA guideline describes. No fetched source describes her own experiences of access to care, and none is invented.
- Laterality of the ankle-brachial index. LOINC 77194-9 (ankle-brachial index) has no side; the right and left values carry the same code and are told apart by their labels. The toe-brachial indices use the side-specific LOINC codes.
- Annual wellness visit. A subsequent annual wellness visit at 70 (HCPCS G0439, CPT 99497, G0009, and CPT 90677 in plain text) with the Mini-Cog, PHQ-2, AUDIT-C, Timed Up and Go, PCV20, mammography and bone density orders, hepatitis C screening (negative at three months), and advance care planning with an unnamed agent. The influenza and first recombinant zoster vaccines were given at the October visit.
- Focused visits. The three chronic-care follow-ups (two weeks with the consultation, three months, and five and a half months) are documented as focused visits on the ADA Standards of Care 2026, IWGDF 2023, the 2024 ACC/AHA PAD guideline, the 2023 chronic coronary disease guideline, and the CMID diabetes monograph. Deviation recorded instead of an invented result: the lipid panel due 4 to 12 weeks after atorvastatin was raised was drawn at 13 weeks because she was on tour; no harm, and tests after any change are now booked before tours. The six-month vascular review with ankle-brachial index and duplex falls after the last visit and is recorded as due. The retina-clinic injections and podiatry visits are recorded as procedures on their own dates, outside the clinic visits.
- Consultation. The referral and the consultation by Marcus Okafor-Lane, MD (a fictional vascular surgeon), on the day of the two-week visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: femoropopliteal disease on duplex; supervised exercise with a home plan on tour (completed, walking distance tripled); low-dose rivaroxaban with aspirin (started that day, no bleeding); no revascularization now, with stated triggers (none occurred, and the decision was confirmed at five and a half months); ezetimibe if LDL stayed at 55 mg/dL or above (added at three months) and semaglutide worth considering (started at three months); and review at six months.
- Synthetic content. All visits, laboratory values, indices, acuity, CGM data, vital signs, scores, the medicines and doses, the procedures, her height (165 cm) and weight, and the modern social history are synthetic. Qualitative results (duplex, hepatitis C, mammogram) appear only in the note text.
- Not used. Biographies, documentaries, interviews about her health other than the 1989 quotation, accounts by her family, staff, or physicians, and reports of her last concerts were not used. One secondary source’s report of heart failure and a valve replacement in 1986 was not corroborated and is not used.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-08-10 Progress note 04 (C-CDA) | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Due 4 to 12 weeks after atorvastatin was raised; drawn today at 13 weeks, one week late, because she was on tour. LDL 64 mg/dL, above goal; no harm from the one-week delay. Corrective action: lipid tests after any change are booked before she leaves on tour |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-05-26 Progress note 02 (C-CDA) | Self-management | Supervised exercise therapy | Ordered | Hospital program starts next week; home walking plan for tour weeks |
2026-05-26 Progress note 02 (C-CDA) | Referral | Retinal examination and visual acuity | Ordered | Retina clinic next week for the right macular edema |
2026-06-15 Progress note 03 (C-CDA) | Prevention | Breast cancer screening | Ordered | Mammogram every two years to 74; last one two years ago |
2026-06-15 Progress note 03 (C-CDA) | Prevention | Osteoporosis screening | Ordered | Bone density scan recommended at 65 and older; none on record |
2026-06-15 Progress note 03 (C-CDA) | Prevention | Hepatitis C screening | Ordered | One-time screening for adults through 79; added to the three-month tests |
Evidence to check
Retrospective claims (R)
None.
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-05-11 | Hemoglobin A1c | 8.6% (high) | High |
| 2026-05-11 | Glucose | 168 mg/dL (high) | High |
| 2026-05-11 | HDL cholesterol | 44 mg/dL (low) | Low |
| 2026-05-11 | Ankle-brachial index, right | 0.62 (low) | Low |
| 2026-05-11 | Ankle-brachial index, left | 0.74 (low) | Low |
| 2026-05-11 | Toe-brachial index, right | 0.46 (low) | Low |
| 2026-05-11 | Toe-brachial index, left | 0.55 (low) | Low |
| 2026-05-11 | Best-corrected visual acuity, right eye (ETDRS letters) | 64 (low) | Low |
| 2026-08-10 | Hemoglobin A1c | 7.6% (high) | High |
| 2026-08-10 | HDL cholesterol | 46 mg/dL (low) | Low |
| 2026-08-10 | Best-corrected visual acuity, right eye (ETDRS letters) | 71 (low) | Low |
| 2026-10-26 | Hemoglobin A1c | 7.1% (high) | High |
| 2026-10-26 | HDL cholesterol | 47 mg/dL (low) | Low |
| 2026-10-26 | Best-corrected visual acuity, right eye (ETDRS letters) | 75 (low) | Low |